Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADERSHIP 301
2016-000906-12Phase 3Terminated
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AQX-1125 in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) (3 arms), sponsored by Aquinox Pharmaceuticals. Primary endpoint: Change in maximum daily bladder pain score at Week 12. Started Jul 2016; status: terminated.
02
Drugs
AQX-1125
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on 2016-000906-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000906-12.